RGRX (Regenerx Biopharmaceuticals) ROCE %: 0.00% (As of Mar. 2023)


What is Regenerx Biopharmaceuticals ROCE %?

Regenerx Biopharmaceuticals RGRX ROCE % is 0.00% as of Mar. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Regenerx Biopharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2023 was 0.00%.

Regenerx Biopharmaceuticals  (OTCPK:RGRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Regenerx Biopharmaceuticals ROCE % Related Terms

Regenerx Biopharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals ROCE % Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -573.85 -415.11 -252.83 -410.54

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -194.76 -432.06 -556.86 0.00 0.00

Regenerx Biopharmaceuticals ROCE % Calculation

Regenerx Biopharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-1.402/( ( (1.285 - 0.43) + (0.382 - 0.554) )/ 2 )
=-1.402/( (0.855+-0.172)/ 2 )
=-1.402/0.3415
=-410.54 %

Regenerx Biopharmaceuticals's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=-1.22/( ( (0.382 - 0.554) + (0.187 - 1.8) )/ 2 )
=-1.22/( ( -0.172 + -1.613 )/ 2 )
=-1.22/-0.8925
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Regenerx Biopharmaceuticals (RGRX) has a ROCE % of 0.00% as of Mar. 2023.
Is Regenerx Biopharmaceuticals' ROCE % too high?
Regenerx Biopharmaceuticals' current ROCE % is 0.00%.
How does Regenerx Biopharmaceuticals' ROCE % compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Regenerx Biopharmaceuticals's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current ROCE % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.